Cerevel Therapeutics Holdings Inc

NASDAQ:CERE   3:59:56 PM EDT
32.82
+2.66 (+8.82%)
Earnings Announcements

Cerevel Therapeutics Posts Q3 Loss Of 43 Cents Per Share

Published: 11/10/2021 11:50 GMT
Cerevel Therapeutics Holdings Inc (CERE) - Cerevel Therapeutics Reports Third Quarter 2021 Financial Results and Pipeline Updates.
Cerevel Therapeutics Holdings Inc - Phase 1 Data for Darigabat in Acute Anxiety Now Expected by End of Q1 2022.
Cerevel Therapeutics Holdings Inc - Cash Balance As of Sept 30 is Expected to Fund Co's Operations Into 2024.
Cerevel Therapeutics Holdings Inc - Qtrly Net Loss per Share, Basic and Diluted $0.43.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.44

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.39

More details on our Analysts Page.